Skip to main content

Table 1 First-line treatment in soft tissue sarcomas: prospective evidence

From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Study Study phase Drug and schedule Patients Overall response rate (%) Progression-free survival (months) Overall survival (months)
Cytotoxic agents
Judson et al., 2014 [2] III Arm A: D (75 mg/m2) 3-weekly
Arm B: D (25 mg/m2/day, days 1–3) + I (10 g/m2 over 4 days) 3-weekly
Arm A: 228
Arm B: 227
Arm A: 14
Arm B: 26
Arm A: 4.6
Arm B: 7.4
Arm A: 12.8
Arm B: 14.3
Chawla et al., 2015 [6] IIb Arm A: D (75 mg/m2) 3-weekly
Arm B: Aldoxorubicin (350 mg/m2) 3-weekly
Arm A: 40
Arm B: 83
Arm A: 0
Arm B: 25
Arm A: 2.7
Arm B: 5.6
Arm A: 14.3
Arm B: 15.8
Gupta et al., 2016 [9] II Amrubicin 40 mg/m2/day, days 1–3, 3 weekly 24 13 5.8 26
Ryan et al., 2016 [3] III Arm A: D (75 mg/m2) + P (150 mg/m2/day, days 1–3) 3-weekly
Arm B: D (75 mg/m2) + placebo, 3-weekly
Arm A: 227
Arm B: 221
Arm A: 28.3
Arm B: 19.9
Arm A: 6
Arm B: 5.2
Arm A: 15.9
Arm B: 16.9
Tap et al., 2016 [4] III Arm A: Evofosfamide (300 mg/m2) + D (75 mg/m2), 3-weekly
Arm B: D (75 mg/m2) 3-weekly
Arm A: 317
Arm B: 323
Arm A: 28.4
Arm B: 18.3
Arm A: 6.3
Arm B: 6
Arm A: 18.4
Arm B: 19
Seddon et al., 2015 [12] III Arm A: G (625 mg/m2 day 1 and 8) + Doc (75 mg/m2 day 8), 3-weekly
Arm B: D (75 mg/m2), 3-weekly
Arm A: 128
Arm B: 129
Arm A: 58.6
Arm B: 65.9
Arm A: 5.6
Arm B: 5.3
Arm A: 14.7
Arm B: 16.5
Bui-Nguyen et al., 2015 [13] II b Arm A: T (1.3 mg/m2) 3-hour infusion, 3-weekly
Arm B: T (1.5 mg/m2) 24-hour infusion, 3-weekly
Arm C: D (75 mg/m2) 3-weekly
Arm A: 47
Arm B: 43
Arm C: 43
Arm A: 14.8
Arm B: 4.7
Arm C: 25.6
Arm A: 2.8
Arm B: 3.1
Arm C: 5.5
NA
Martin-Broto et al., 2016 [14] II Arm A: T (1.1 mg/m2) 3-hours infusion + D (60 mg/m2), 3-weekly
Arm B: D (75 mg/m2), 3-weekly
Arm A: 54
Arm B: 59
Arm A: 17
Arm B: 17
Arm A: 5.7
Arm B: 5.5
Arm A: 13.3
Arm B: 13.7
Gelderblom et al., 2014 [15] II Arm A: Brostallicin (10 mg/m2), 3-weekly
Arm B: D (75 mg/m2), 3-weekly
Arm A: 79
Arm B: 39
Arm A: 3.9
Arm B: 22
Arm A: 1.6
Arm B: 6
NA
Biological agents
Tap et al., 2016 [11] Ib/II Arm A: Olaratumab (15 mg/kg) day 1 and 8 + D (75 mg/m2); 3-weekly
Arm B: D (75 mg/m2), 3-weekly
Arm A: 66
Arm B: 67
Arm A: 18.2
Arm B: 11.9
Arm A: 6.6
Arm B: 4.1
Arm A: 26.5
Arm B: 14.7
  1. D doxorubicine; I ifosfamide; P palifosfamide; G gemcitabine; Doc docetaxel; T trabectedin; NA not available
\